Brukinsa (zanubrutinib)
Pharmacy benefit prior authorization and quantity limit policy for zanubrutinib (Brukinsa) including specialty pharmacy requirement, coverage criteria for mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom's macroglobulinemia, continuation/reauthorization and quantity limits.
References updated: Effective 4/1/23
Coverage Summary
Coverage stance: covered_with_criteria. Subject: Brukinsa (zanubrutinib). Scope: Pharmacy benefit prior authorization and quantity limit policy for zanubrutinib including specialty pharmacy requirement, coverage criteria for mantle cell lymphoma, marginal zone lymphoma, and Waldenstrom's macroglobulinemia, continuation/reauthorization, and quantity limits.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.